ATXI - アベニュ―・セラピュ―ティクス （Avenue Therapeutics Inc.） アベニュ―・セラピュ―ティクスATXIのチャート
ATXIの企業情報
| symbol | ATXI |
|---|---|
| 会社名 | Avenue Therapeutics Inc （アベニュ―・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Avenue Therapeutics Inc. is a pharmaceutical company. The Company is engaged in acquiring licensing developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol an intravenous formulation of tramadol hydrochloride (HCl) for the management of moderate to moderately severe postoperative pain. Tramadol a synthetic dual-acting opioid is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31 2016 the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers. アベニュ―・セラピュ―ティクスは米国の専門医薬品企業。主に手術後の中程度から重度の疼痛緩和に特化した医薬品の開発・商品化に従事する。合成二重作用性オピオイドで有効性と安全性のあるトラマド―ルHCIの臨床デ―タを活用し、トラマド―ルHCI静脈内製剤の開発に焦点を当てる。本社はニューヨーク。 Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. |
| 本社所在地 | 2 Gansevoort Street 9th Floor New York NY 10014 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 781-652-4500 |
| 設立年月日 | 42125 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.avenuetx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/atxi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -24.27900 |
| 終値（lastsale） | 2.36 |
| 時価総額（marketcap） | 24908431.2 |
| 時価総額 | 時価総額（百万ドル） 26.38605 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 17.44605 |
| 当期純利益 | 当期純利益（百万ドル） -24.22500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Avenue Therapeutics Inc revenues was not reported. Net loss increased from $3.1M to $15M. Higher net loss reflects Research and development increase from $580K to $13.2M (expense) General and administrative increase of 15% to $1.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.37 to -$1.48. |
ATXIのテクニカル分析
ATXIのニュース
Avenue Therapeutics makes progress in securing approval for Tramadol trial 2023/04/18 14:43:23 Seeking Alpha
Avenue Therapeutics (ATXI) was trading around +4% on Tuesday after reporting progress in its efforts to secure approval for a Phase 3 clinical trial of its intravenous Tramadol.The…
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol 2023/04/17 20:01:00 GlobeNewswire
MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has received official meeting minutes from the Type C meeting with the U.S. Food and Drug Administration (“FDA”) conducted on March 9, 2023, regarding the development of intravenous (“IV”) Tramadol for the treatment of post-operative pain. The purpose of this meeting was to discuss and reach agreement with the FDA on the proposed study protocol that would assess the risk of opioid-induced respiratory depression related to opioid stacking on IV Tramadol compared to IV morphine.
Avenue Therapeutics Announces 1.94M Share Offering by Selling Stockholders 2023/04/11 10:07:01 Investing.com
https://www.investing.com/news/assorted/avenue-therapeutics-announces-194m-share-offering-by-selling-stockholders-432SI-3052308
Avenue Therapeutics GAAP EPS of -$1.63 2023/03/31 04:51:41 Seeking Alpha
Avenue Therapeutics press release (ATXI): FY GAAP EPS of -$1.63.As of December 31, 2022, our cash and cash equivalents totaled $6.7 million, compared to $3.8 million at December 31,…
Ocean Biomedical, Avenue top healthcare gainers; InVivo, Akebia lead losers'' pack 2023/03/09 15:01:05 Seeking Alpha
Ocean Biomedical OCEA +57%. Avenue Therapeutics (ATXI) +21%. InVivo Therapeutics NVIV -49%. Akebia Therapeutics (AKBA) -22%.
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI) 2023/01/31 18:30:00 Accesswire
NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Therapeutics, Inc. Avenue Therapeutics, Inc. (Nasdaq:ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. Avenue is headquartered in Miami, Florida and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, please visit: https://www.avenuetx.com About Aegis Capital Corporation Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
Avenue Therapeutics Announces $3.25 Million Registered 2023/01/27 19:19:43 Medium
Continue reading on Medium »
Avenue Therapeutics Inc. (ATXI) is an excellent investment, but the stock is overvalued/undervalued right now 2023/01/23 16:08:00 US Post News
The share price of Avenue Therapeutics Inc. (NASDAQ:ATXI) rose to $1.50 per share on Friday from $1.49. While Avenue Therapeutics Inc. has overperformed by 0.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATXI fell by -87.65%, with highs and lows ranging from $18.75 to $1.06, […]
Is Avenue Therapeutics Inc. (NASDAQ: ATXI) A Stock A New Investor Should Consider Now? 2023/01/19 15:00:00 Stocks Register
Avenue Therapeutics Inc. (NASDAQ:ATXI) shares, rose in value on Wednesday, 01/18/23, with the stock price down by -21.11% to the previous day’s close as strong demand from buyers drove the stock to $1.57. Actively observing the price movement in the last trading, the stock closed the session at $1.99, falling within a range of $1.57 … Is Avenue Therapeutics Inc. (NASDAQ: ATXI) A Stock A New Investor Should Consider Now? Read More »
Pre-Market Steady Movements: Avenue Therapeutics, Inc. (NASDAQ:ATXI -21.11%), Invitae Corporation (NYSE:NVTA -2.27%) 2023/01/19 14:04:02 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Pre-Market Steady Movements: Avenue Therapeutics, Inc. (NASDAQ:ATXI -21.11%), Invitae Corporation (NYSE:NVTA -2.27%) appeared first on Stocks Equity .
Is Avenue Therapeutics Inc. (NASDAQ: ATXI) Still A Buy After sinking -4.79% Last Week? 2022/11/17 15:00:00 Marketing Sentinel
During the last session, Avenue Therapeutics Inc. (NASDAQ:ATXI)’s traded shares were 1.31 million, with the beta value of the company hitting -0.56. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday gain of 7.83% or $0.13. The 52-week high for the ATXI share is $26.85, that puts it down … Is Avenue Therapeutics Inc. (NASDAQ: ATXI) Still A Buy After sinking -4.79% Last Week? Read More »
Avenue Therapeutics GAAP EPS of -$0.45 2022/11/15 13:30:10 Seeking Alpha
Avenue Therapeutics press release (ATXI): Q3 GAAP EPS of -$0.45.As of September 30, 2022, Avenue’s cash and cash equivalents totaled $0.2M, compared to $3.8M at December 31, 2021.
Have you been able to find a good deal on Avenue Therapeutics Inc.’s shares? 2022/11/07 16:48:00 US Post News
The share price of Avenue Therapeutics Inc. (NASDAQ:ATXI) fell to $1.78 per share on Friday from $1.99. While Avenue Therapeutics Inc. has underperformed by -10.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATXI fell by -92.67%, with highs and lows ranging from $27.75 to $1.98, […]
US Stocks Open Lower; Dow Drops Over 100 Points 2022/10/14 14:59:57 Benzinga
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.37% to 29,927.92 while the NASDAQ fell 1.44% to 10,495.56. The S&P 500 also fell, dropping, 0.98% to 3,634.00. Also check this: Market Volatility Declines Following US Inflation Data Leading and Lagging Sectors Health care shares fell by just 0.4% on Friday. Leading the sector was strength from Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) and Valneva SE (NASDAQ: VALN ). In trading on Friday, energy shares dipped by 2.9%. Top Headline US retail trade came in unchanged for September, missing market estimates for a 0.2% rise. Equities Trading UP Gravitas Education Holdings, Inc. (NASDAQ: GEHI ) shares shot up 78% to $26.65. Shares of Avenue Therapeutics, Inc. (NASDAQ: ATXI ) got a boost, shooting 43% to $3.4806. Avenue Therapeutics recently priced a roughly 3.6 million unit offering at $3.30 per unit. IMARA Inc. (NASDAQ: IMRA ) shares were also up, gaining 35% to $3.47 after the …